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Abstract
Background: This study aimed to i) examine the frequency of C9orf72 expansions in a cohort of patients with the
behavioural variant frontotemporal dementia (bvFTD) phenocopy syndrome, ii) observe outcomes in a group of
phenocopy syndrome with very long term follow-up and iii) compare progression in a cohort of patients with the
phenocopy syndrome to a cohort of patients with probable bvFTD.
Methods: Blood was obtained from 16 phenocopy cases. All met criteria for possible bvFTD and were labeled as
phenocopy cases if they showed no functional decline, normal cognitive performance on the Addenbrooke’s Cognitive
Examination-Revised (ACE-R) and a lack of atrophy on brain imaging, over at least 3 years of follow-up. In addition, we
obtained very long term follow-up data in 6 cases. A mixed model analysis approach determined the pattern of change
in cognition and behaviour over time in phenocopy cases compared to 27 probable bvFTD cases.
Results: All 16 patients were screened for the C9orf72 expansion that was present in only one (6.25%). Of the 6 cases
available for very long-term follow-up (13 - 21 years) none showed progression to frank dementia. Moreover, there was
a decrease in the caregiver ratings of behavioural symptoms over time. Phenocopy cases showed significantly slower
rates of progression compared to probable bvFTD patients (p < 0.006).
Conclusion: The vast majority of patients with the bvFTD phenocopy syndrome remain stable over many years. An
occasional patient can harbor the C9orf72 expansion. The aetiology of the remaining cases remains unknown but it
appears very unlikely to reflect a neurodegenerative syndrome due to lack of clinical progression or atrophy on imaging.
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Background
The classical features of behavioural variant Frontotemporal
Dementia (bvFTD) syndrome are well established. The
current consensus criteria incorporates cognitive, behav-
ioural, neuroimaging, genetic and pathological parameters,
to provide a framework to make accurate diagnoses by rank-
ing the level of diagnostic certainty as possible, probable and
definite [1]. Although the accuracy of these criteria has been
pathologically validated, controversy still exists regarding the
aetiology, progression and prognosis of possible bvFTD [2].
A recent study which followed FTD patients over a five year
period found that a number of possible bvFTD patients
remain in this category for many years and appear not to
progress on cognitive and behavioural measures [3]. A num-
ber of these patients are classified as ‘phenocopy syndrome’
cases [4–7]. Patients harboring the C9orf72 expansion may
also satisfy criteria for possible, but not probable, bvFTD at
first presentation and may be atypical with pervasive psych-
otic features [3]. Moreover, cases who have been labeled as
the ‘phenocopy syndrome’ have also been reported to carry
the C9orf72 expansion [8, 9]. The question remains, just
how many of the phenocopy cases have the expansion?
The present study sought to address this issue by explor-
ing the outcomes in a large and unique cohort of phenocopy
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patients that have been followed over many years and
screened for the C9orf72 expansion. A mixed model analysis
was employed to determine the rate of change in global cog-
nition and behaviour over time in these phenocopy cases
compared to a group of patients with probable bvFTD.
Methods
Patients
Patients were assessed at the specialist early-onset demen-
tia clinic at Addenbrooke’s Hospital Cambridge between
1993 and 2007. Patients who satisfied criteria for possible
bvFTD only, and were seen on at least two occasions; with
initial and follow-up evaluation at least 3 years apart, and
in whom blood had been obtained for gene screening,
were included in the study. Patients were excluded from
the study if they progressed to probable bvFTD over the
study period. Exclusion criteria also included a current or
past medical history of a psychiatric condition, traumatic
brain injury, drug or alcohol abuse and cerebrovascular
disease. Of note patients who experienced delusions or
hallucinations were included in the study.
Of the 16 cases, three were still under regular review in
the clinic in 2014. We attempted to contact the remainder
and we able to reassess three additional cases. Thus very
long term follow-up (ranging from 13 to 21 years) was
available in 6 cases.
A group of probable bvFTD patients were included in
the study to serve as a comparison group for the mixed
model analysis, to determine differences in progression
rates. These patients (n = 27) were assessed at FRONTIER,
a frontotemporal dementia specialist research clinic and
met probable diagnostic criteria for bvFTD. They were
matched for age, sex and education to the phenocopy cases.
Patients with probable bvFTD who were subsequently
found to carry the C9orf72 expansion were not included in
this group. None of these patients carried a GRN orMAPT
mutation. The results below relate to the phenocopy cases
only unless otherwise stated.
Patients were classified according to the current inter-
national diagnostic criteria [1]. Patients were classified
as possible bvFTD when they met three of the six core
behavioural features of bvFTD, but had normal brain
imaging and an absence of typical genetic or patho-
logical findings. Probable bvFTD, criteria was met when
patients firstly satisfied possible criteria with additional
evidence of functional decline, and frontal or temporal
abnormalities on MRI or Fludeoxyglucose (18F)-Positron
emission tomography (FDG-PET) [1]. In this study MRI
scans were performed in all cases and a validated visual
rating scale, assessed atrophy of the orbitofrontal cortex,
anterior temporal poles and insular cortex, according to
previously published data [10, 11]. Atrophy was rated on a
Likert scale by a blinded rater after appropriate training on
an independent data set. Intra-class correlation coefficient
to assess inter-rater reliability was very high (Cronbach’s
alpha = .9).
Clinical assessment
A comprehensive clinical assessment was conducted
with the patient and behavioural symptoms were
explored with the carer using the CBI (Cambridge
Behavioural Inventory), [12]; a higher score indicates
greater impairment (maximum score – 316). Global
cognitive function was measured using the Addenbrooke’s
Cognitive Examination-Revised (ACE-R) [13]; a normal
score > 88/100.
Genetic screening
Blood samples were screened at the Medical Research
Council Prion Unit, London, or at NeuRA, Sydney,
for the C9orf72 expansion based on the repeat-
primed polymerase chain reaction technique as previ-
ously described by Renton [14]. Genomic DNA was
extracted from blood according to standard proce-
dures. Samples were scored as expansion-positive if
they harbored > 30 repeats. C9orf72 hexanucleotide
repeat non-expansion alleles were detected by poly-
merase chain reaction amplification and capillary
electrophoresis.
Statistical analysis
Data were analyzed using SPSS 22.0 statistical package.
Normal distribution was determined by means of
Kolmogorov-Smirnoff tests. Parametric variables were
compared across groups via independent t-tests and
analysis of variance (ANOVA). Non-parametric data
were analyzed using Mann-Whitney and Kruskal-Wallis
tests, and Chi-Square tests compared categorical data.
Linear mixed effect models examined change in perform-
ance over time [15]. Such measures are useful in these
circumstances as they take into account the variability in
follow-up time within the phenocopy and probable bvFTD
groups, and the significant difference in follow-up between
the two groups.
Results
Patients
Between 1993 and 2007 a total of 89 patients with
possible bvFTD were assessed and followed for at
least 3 years in the specialist clinic. Of these 89, a
diagnosis of probable bvFTD became apparent on fol-
low up in 63 (Fig. 1). The remaining 26 were given a
label of phenocopy syndrome on the basis of a lack
of progression with relative preservation of activities
of daily living, maintained performance on the ACE-R
and a normal MRI as assessed by a validated visual
rating scale.
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Within the comparison bvFTD group, four patients
have now come to autopsy and each of these patients
showed FTLD pathology including TDP-43 in one, TAU
in another and FUS in another.
Blood sampling was obtained in all cases attending the
clinic in 2007. In the phenocopy cohort of 26 cases,
blood was available in 16 for genotyping.
Genetic testing
The C9orf72 expansion was present in one of 16 patients
who had blood obtained for genotyping, representing 6.25%
of the cohort. This patient was male and in his 60’s when
he presented with a two-year history of behavioural change.
At presentation his score on the CBI of 152 was very high
and on the ACE-R his score of 81 was just below the cut-
off of 88. A MRI scan was normal. When last seen in 2006
scores, had improved with a CBI score of 136 and an ACE-
R score of 89. An FDG-PET scan showed no areas of
significant brain hypometabolism. He was then lost to
follow up in 2008 (11 years after onset) and died of an
unrelated condition in 2010. Unfortunately post mortem
brain examination was not performed.
Cognitive and behavioural measures at baseline and
follow-up
The 16 phenocopy patients with available genotyping
comprised 15 men with a mean age of 55.7 (range 47 to
69 years). Twelve of the 16 were under 65. The mean
follow-up time was 8 years. Table 1 demonstrates the
baseline demographic information for these 16 cases and
the comparison group of probable bvFTD patients and
includes the mean ACE-R and the CBI scores on first
assessment and length of follow-up for the phenocopy
and the probable bvFTD group.
At presentation 10 of the 16 phenocopy patients
scored above 88 on the ACE-R, and none of the remain-
der scored below 80/100. At last follow-up six of these
patients still scored within the normal range. The profile
of behavioural symptoms at presentation and last follow-
up was typical of bvFTD with high endorsements for
motivation (apathy), stereotyped and abnormal behaviours,
changed appetite and eating and mood.
At presentation there was a significant difference in
the ACE-R scores between the phenocopy cases and the
probable bvFTD group (p = 0.001); the mean ACE-R
score in the phenocopy group was 89/100, whereas the
mean score for the probable bvFTD group was 73/100.
Fig. 1 Longitudinal changes in diagnosis and genetic findings. Flowchart demonstrating the number of patients from the Cambridge cohort at
presentation with possible bvFTD, according to diagnostic criteria for bvFTD, and the change in diagnosis and subsequent genetic findings over
the follow-up period
Table 1 Phenocopy cases – demographic details
Demographics at Presentation Phenocopy
bvFTD
(n = 16)
Probable
bvFTD
(n = 27)
P value
Age at Onset, yrs 55.7 ± 6.3 59.7 ± 8.1 0.1
Sex (M:F) 15:1 22:5 0.4
Disease Duration, yrs. 3.9 ± 2.3 3.8 ± 2.4 0.1
Education, yrs. 11.4 ± 2.1 12.4 ± 3.4 0.3
ACE-R 89.2 ± 6.4 72.8 ± 14.6 0.001
CBI 91.3 ± 59 72.5 ± 21.5 0.3
Follow-up, yrs. 7.3 ± 4.2 3.2 ± 1.3 0.002
Demographic information (Mean ± standard deviation scores) for the
phenocopy cases with blood available for C9orf72 expansion testing, and
probable bvFTD cases. bvFTD behavioural variant frontotemporal dementia,
ACE-R Addenbrooke’s Cognitive Examination-Revised, CBI Cambridge
Behavioural Inventory
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In contrast both groups had equivalently high scores on
the CBI (p = 0.3).
The phenocopy group was then compared to a group
of probable bvFTD cases using a mixed model analysis
that took into account the variability of follow-up within
and between the two groups. On a measure of global
cognitive function, the ACE-R, the groups combined
showed significant deterioration over time (p < 0.001)
with a significant interaction between disease group and
time (p = 0.006) indicating a faster rate of decline in
probable bvFTD cases compared to phenocopy cases
(Fig. 2). On a measure of behaviour, the CBI, the group
as a whole showed significant deterioration over time
(p < 0.001), however while the interaction between disease
group and time was not significant there was a statistical
trend (p < 0.06) suggesting a faster deterioration in be-
haviour in the probable bvFTD group compared to the
phenocopy group.
The mean ACE-R and CBI scores with 95% confidence
intervals, calculated according to the mixed model statis-
tic, for standard times intervals, are demonstrated for the
ACE-R and CBI in Table 2. Table 2 also shows the mean
ACE-R and CBI scores at last follow-up for the phenocopy
and probable bvFTD group; these are for illustrative
purposes only as the follow-up times were variable within
and between the groups and therefore statistical analysis
based on these measures is not appropriate. MRI at baseline and follow-up
Grey matter density was judged as normal (0) or within
normal range (1) in the orbitofrontal cortex, anterior
temporal poles and insular cortex in each of the pheno-
copy cases at baseline and at follow-up.
Long-term clinical follow-up
In 2013 we attempted to contact the caregivers of the 15
living cases by post and to arrange a telephone interview.
Three were still attending the clinic at regular intervals
and we were successful in another three (total six), with
lengths of follow-up ranging from 13 to 21 years from first
visit to the clinic. All were living at home; 3 remained in
the same relationship as at their presentation, and there
had been no cases with progression to frank dementia.
Discussion
This study provides evidence for the validity of the
bvFTD phenocopy syndrome. Only one of 16 phenocopy
cases (6.25%) had the C9orf72 expansion and it is inter-
esting to note that this is the only patient in the cohort
who is known to have died. This study had the benefit of
very long-term follow-up information, between 13 and
21 years, in 6 cases. There was no evidence of progres-
sion to frank dementia in any of the phenocopy cases
over many years of follow-up.
The underlying aetiology of the phenocopy syndrome
is unknown. On a clinical level, these patients present
Fig. 2 Longitudinal changes in ACE-R and CBI – phenocopy and
bvFTD cases. a demonstrates estimated marginal means based on the %
change in ACE-R score across time for phenocopy and probable bvFTD
cases. Time (p< 0.001). Time x Diagnosis (p= 0.006). b demonstrates
estimated marginal means based on the change in CBI scores across
time. Time (p< 0.001). Time x Diagnosis (p= 0.06)
Table 2 Phenocopy and bvFTD cases - Longitudinal changes in
ACE-R and CBI
Time Phenocopy bvFTD (n = 16) Probable bvFTD (n = 27)
ACE-R – Scores (mean, 95% CI)
Day 1 92 (84.1-99.9) 72 (65.7-78.3)
Day 180 91.6 (84.1-99.2) 69.5 (63.8-75.2)
Day 360 91.3 (84-98.6) 67 (61.5-72.5)
Day 540 91 (83.8-98.1) 64.5 (58.8-70.2)
Day 720 90.6 (83.7-97.5) 62 (55.7-68.2)
CBI Scores (mean, 95% CI)
Day 1 81.8 (62.7-101) 75.7 (60.7-90.7)
Day 180 81.8 (63.4-100.1) 79.6 (66.1-93)
Day 360 81.7 (64.1-99.4) 83.4 (70.5-96.3)
Day 540 81.7 (64.6-98.8) 87.2 (73.9-100.6)
Day 720 81.6 (65-98.2) 91.1 (76.3-105.9)
Last Follow-up (mean, SD)
ACE-R 85.1 ± 7.1 54.2 ± 23.6
CBI 77 ± 47.3 93.9 ± 33.7
Follow-up data according to the mixed model analysis with standard time
intervals generated by the model, for phenocopy and probable bvFTD cases.
Bottom rows show the mean ACE-R and CBI scores at last follow-up. CI confidence
interval, SD standard deviation, bvFTD behavioural variant frontotemporal dementia,
ACE-R addenbrooke’s cognitive examination-Revised, CBI Cambridge
behavioural inventory
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with cognitive and behavioural changes, that are identical
to the deficits seen in probable bvFTD cases, yet do not
show significant brain atrophy [6, 16]. Furthermore, a pre-
vious clinicopathological study found that 2 phenocopy
cases did not have FTLD pathology at autopsy [17]. While
it is possible that the phenocopy syndrome represents a
late onset decompensated developmental disorder in the
Asperger-Autism spectrum, it remains to be proven. In
keeping with this hypothesis, such patients, although
scoring normally on tests such as the ACE-R and measures
of memory, may show mild deficits on tests of inhibitory
control and emotion processing [18] as do patients on
the Asperger-Autism spectrum [19, 20]. A recent study
comparing phenocopy and probable bvFTD cases showed
a high rate of adverse life events, relationship problems
and cluster C personality traits comprising the avoidant,
dependent, and obsessive-compulsive personality traits
[21]. Putting these findings together it seems highly likely
that the phenocopy syndrome is a final common pathway
for a complex interaction of a number of personality and
psychiatric factors.
Interestingly long-term assessments show that, although
some patients continue to exhibit behavioural symptoms,
these symptoms are rated as less marked by caregivers
over time. This could, of course, simply reflect the fact
that family members adjust to and are less troubled by the
symptoms. A study of possible bvFTD patients followed
over several years showed that a subgroup, many of whom
had the C9orf72 expansion, progressed on cognitive and
functional measures while others, who lacked the expan-
sion, demonstrated no change and conformed, therefore,
to the phenocopy syndrome [3]. Although the former
work did not have the benefit of such long-term follow-
up, it mirrors the results from this study, which showed
that the phenocopy cases did not progress on the
CBI, and together these findings point towards a non-
progressive non-neurodegenerative aetiology in phenocopy
cases. The probable bvFTD patients were also significantly
more impaired on the ACE-R at presentation, and the
mixed model analysis revealed a significant deterioration
in ACE-R scores over time in the probable bvFTD group
compared to the phenocopy group further demonstrating
the relative cognitive stability of phenocopy cases.
Studies of FTD have established that the C9orf72
expansion, whilst variable in prevalence around the
world, is a common Mendelian genetic cause of familial
disease, and is also present in a proportion of sporadic
cases [22]. The full clinical spectrum associated with
the expansion is not yet clear but it has been shown that
such patients have a high rate of psychotic symptoms and
that there is considerable variability in the rate of progres-
sion. While some patients present with a long insidious
history of gradual decline others have a more fulminating
illness [8, 9]. Studies have also linked C9orf72 to other
clinical phenotypes outside of FTD and MND, including
Parkinson’s disease, multiple system atrophy (MSA) and
Alzheimer’s disease (AD), although many lacked neuro-
pathological confirmation [22]. Nonetheless, there does
appear to be partial penetrance as C9orf72 carriers may
remain asymptomatic into their 80’s [23]. We have
confirmed that patients with the phenocopy syndrome
may also harbor the expansion but in a well-characterized
cohort with long term follow up this appears to be the
exception. Interestingly, the only C9orf72 carrier in our
phenocopy cohort did not show any abnormalities on
MRI or FDG-PET, in keeping with reports from prior
studies [8, 9]. Our work provides data to support the
informed genetic counseling of this clinical group. A
lack of understanding of the phenocopy syndrome and
support for the patients and their families can make
recruitment into a research programme difficult. Nonethe-
less further work is necessary to confirm the proportion of
the FTD phenocopy syndrome that has a genetic aetiology
and also to confirm the underlying pathology in these
cases. Moreover, study of the phenocopy syndrome may
help clarify the link between psychiatric illness and fronto-
temporal dementia. As in this project, cases that have a
psychiatric history are usually excluded from studies
however this design may need to be reconsidered in the
future in light of this apparent link and co-existence of
psychiatric and neurodegenerative disorders.
Conclusion
We propose that the phenocopy syndrome is a valid entity.
These patients are almost always male and experience
symptom onset between the ages of 45 and 65. Despite re-
ported behavioural changes, they perform relatively nor-
mally on general cognitive tests such as the ACE-R or
ACE-III, have preserved basic activities of daily living, lack
atrophy on MRI and critically show no decline after 3 years
of follow-up. Within the first two to 3 years of evaluation
of possible bvFTD cases physicians should exhibit caution
in diagnosing the phenocopy syndrome, since the majority
will progress to probable disease over time and almost one
half will progress within the first 3 years. It should be also
stressed that although phenocopy cases may not harbour
underlying neurodegenerative pathology, this is not a
benign condition and caregiver burden can be high.
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